Bonita Rup
Genetics Institute, Inc.
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Bonita Rup.
Cancer | 1994
Hideki Yoshikawa M.D.; Wolfgang J. Rettig; Joseph M. Lane; Kunio Takaoka; Edward Alderman; Bonita Rup; Vicki Rosen; John H. Healey; Andrew G. Huvos; Pilar Garin-Chesa
Background. Bone morphogenetic proteins (BMPs) are potent inducers of bone formation. Functional and immunohistochemical studies have identified BMPs in a subset of osteosarcomas. In the present study, the authors extend the analysis of BMP expression to other bone and soft tissue sarcomas.
Cancer | 1994
Hideki Yoshikawa M.D.; Wolfgang J. Rettig; Kunio Takaoka; Edward Alderman; Bonita Rup; Vicki Rosen; M. John Wozney; Joseph M. Lane; Andrew G. Huvos; Pilar Garin-Chesa
Background. Bone morphogenetic proteins (BMP) induce ectopic bone formation in vivo and may play a role in normal bone development. In addition, bone morphogenetic activity, as measured in a bone‐forming assay in immunodeficient, athymic nu/nu mice, is present in a proportion of osteosarcomas; this activity, which may be mediated by BMP, is correlated with a poor prognosis.
Aaps Journal | 2007
Bonita Rup; Denise O'hara
Throughout the life cycle of biopharmaceutical products, bioanalytical support is provided using ligand binding assays to measure the drug product for pharmacokinetic, pharmacodynamic, and immunogenicity studies. The specificity and selectivity of these ligand binding assays are highly dependent on the ligand binding reagents. Thus the selection, characterization, and management processes for ligand binding reagents are crucial to successful assay development and application. This report describes process considerations for selection and characterization of ligand binding reagents that are integral parts of the different phases of assay development. Changes in expression, purification, modification, and storage of the ligand binding reagents may have a profound effect on the ligand binding assay performance. Thus long-term management of the critical ligand binding assay reagents is addressed including suggested characterization criteria that allow ligand binding reagents to be used in as consistent a manner as possible. Examples of challenges related to the selection, modification, and characterization of ligand binding reagents are included.
Blood | 2001
David A. Roth; Craig M. Kessler; K. John Pasi; Bonita Rup; Suzanne G. Courter; Karen L. Tubridy
Thrombosis and Haemostasis | 1995
James C. Keith; Thomas Ferranti; Bibhu Misra; Thomas Frederick; Bonita Rup; Kyle McCarthy; Robert Faulkner; Larry Bush; Robert G. Schaub
Blood | 2003
Karen E. Russell; Eva H. N. Olsen; Robin A. Raymer; Elizabeth P. Merricks; Dwight A. Bellinger; Marjorie S. Read; Bonita Rup; James C. Keith; Kyle McCarthy; Robert G. Schaub; Trimothy C. Nichols
Archive | 2000
Man Sung Co; Maximiliano Vasquez; Beatriz M. Carreno; Abbie Cheryl Celniker; Mary Collins; Samuel J. Goldman; Gary S. Gray; Andrea Knight; Denise O'hara; Bonita Rup; Geertruida M. Veldman
Archive | 1999
Man Sung Co; Maximiliano Vasquez; Beatriz M. Carreno; Abbie Cheryl Celniker; Mary Collins; Samuel J. Goldman; Gary S. Gray; Andrea Knight; Denise O'hara; Bonita Rup; Geertruida M. Veldman
Archive | 2000
Man Sung Co; Maximiliano Vasquez; Beatriz M. Carreno; Abbie Cheryl Celniker; Mary Collins; Samuel Goldman; Gary S. Gray; Andrea Knight; Denise O'hara; Bonita Rup; Geertruida M. Veldman
Archive | 1999
Man Sung Co; Maximiliano Vasquez; Beatriz M. Carreno; Abbie Cheryl Celniker; Mary Collins; Samuel J. Goldman; Gary S. Gray; Andrea Knight; Denise O'hara; Bonita Rup; Geertruida M. Veldman